Unichem Laboratories rises on receiving USFDA approval for Montelukast Sodium Tablets

09 Oct 2015 Evaluate

Unichem Laboratories is currently trading at Rs. 311.10, up by 3.80 points or 1.24% from its previous closing of Rs. 307.30 on the BSE.

The scrip opened at Rs. 307.00 and has touched a high and low of Rs. 320.90 and Rs. 305.00 respectively. So far 135997 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 334.00 on 06-Oct-2015 and a 52 week low of Rs. 174.00 on 08-Jun-2015.

Last one week high and low of the scrip stood at Rs. 334.00 and Rs. 299.00 respectively. The current market cap of the company is Rs. 2838.25 crore.

The promoters holding in the company stood at 50.14% while Institutions and Non-Institutions held 18.62% and 31.25% respectively.


Unichem Laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Montelukast Sodium Tablets. Montelukast Sodium Tablets 10mg are therapeutically equivalent to Singulair Tablets 10mg of Merck Sharp & Dohme Corp.

Montelukast is a leukotriene receptor antagonist (LTRA). The product will be commercialized from Unichem’s Goa plant. The company now has total of 19 ANDA approvals (Including 3 Tentative Approvals) from USFDA.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×